A carregar...
Activation of AMPK sensitizes medulloblastoma to Vismodegib and overcomes Vismodegib‐resistance
Vismodegib, a Smoothened antagonist, is clinically approved for treatment of human basal cell carcinoma (BCC), in the clinical trials of medulloblastoma (MB) and other cancers. However, a significant proportion of these tumors fail to respond to Vismodegib after a period of treatment. Here, we find...
Na minha lista:
| Publicado no: | FASEB Bioadv |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8171304/ https://ncbi.nlm.nih.gov/pubmed/34124601 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1096/fba.2020-00032 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|